The potential role of melatonin on sleep deprivation-induced cognitive impairments: Implication of FMRP on cognitive function

Neuroscience

Volumn 301, Issue , 2015, Pages 403-414

  Kwon, K J ^a,b   Lee, E J ^a   Kim, M K ^a   Jeon, S J ^c   Choi, Y Y ^d   Shin, C Y ^a   Han, S H ^a,b  

^a Konkuk University School of Medicine   (South Korea)

^b Konkuk University Hospital   (South Korea)

^c Kyung Hee University   (South Korea)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

FMRP; Glia; Learning and memory; Melatonin; Oxidative stress; Sleep deprivation

Indexed keywords

4 HYDROXYNONENAL; 8 HYDROXYDEOXYGUANOSINE; FRAGILE X MENTAL RETARDATION PROTEIN; MELATONIN; REACTIVE OXYGEN METABOLITE; 4-HYDROXY-2-NONENAL; 8-OXO-7-HYDRODEOXYGUANOSINE; ALDEHYDE; ANTIOXIDANT; DEOXYGUANOSINE; FMR1 PROTEIN, RAT; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CELL VIABILITY; CHEMOPROPHYLAXIS; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; EMBRYO; GLIA; HIPPOCAMPUS; MALE; MEMORY DISORDER; NERVE CELL CULTURE; NERVE CELL NECROSIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SINGLE DRUG DOSE; SLEEP DEPRIVATION; SPATIAL MEMORY; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN; CELL CULTURE; CELL SURVIVAL; COMPLICATION; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MAMMALIAN EMBRYO; MAZE TEST; MEMORY DISORDERS; METABOLISM; NERVE CELL; SPRAGUE DAWLEY RAT; WISTAR RAT;

ALDEHYDES; ANIMALS; ANTIOXIDANTS; BRAIN; CELL SURVIVAL; CELLS, CULTURED; CEREBRAL CORTEX; DEOXYGUANOSINE; DISEASE MODELS, ANIMAL; EMBRYO, MAMMALIAN; FRAGILE X MENTAL RETARDATION PROTEIN; GENE EXPRESSION REGULATION; MALE; MAZE LEARNING; MELATONIN; MEMORY DISORDERS; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING; SLEEP DEPRIVATION;

EID: 84933574854     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2015.05.079     Document Type: Article

References (67)

1. Anderson G., Maes M. Oxidative/nitrosative stress and immuno-inflammatory pathways in depression: treatment implications. Curr Pharm Des 2013.
2. Bechara E.G., Didiot M.C., Melko M., Davidovic L., Bensaid M., Martin P., Castets M., Pognonec P., Khandjian E.W., Moine H., Bardoni B. A novel function for fragile X mental retardation protein in translational activation. PLoS Biol 2009, 7:e16.
3. Bushey D., Tononi G., Cirelli C. The Drosophila fragile X mental retardation gene regulates sleep need. J Neurosci 2009, 29:1948-1961.
4. Bushey D., Tononi G., Cirelli C. Sleep and synaptic homeostasis: structural evidence in Drosophila. Science 2011, 332:1576-1581.
5. Choi B.R., Lee S.R., Han J.S., Woo S.K., Kim K.M., Choi D.H., Kwon K.J., Han S.H., Shin C.Y., Lee J., Chung C.S., Kim H.Y. Synergistic memory impairment through the interaction of chronic cerebral hypoperfusion and amlyloid toxicity in a rat model. Stroke 2011, 42:2595-2604.
6. Cirelli C., Gutierrez C.M., Tononi G. Extensive and divergent effects of sleep and wakefulness on brain gene expression. Neuron 2004, 41:35-43.
7. Cui W., Mizukami H., Yanagisawa M., Aida T., Nomura M., Isomura Y., Takayanagi R., Ozawa K., Tanaka K., Aizawa H. Glial dysfunction in the mouse habenula causes depressive-like behaviors and sleep disturbance. J Neurosci 2014, 34:16273-16285.
8. D'Almeida V., Hipolide D.C., Azzalis L.A., Lobo L.L., Junqueira V.B., Tufik S. Absence of oxidative stress following paradoxical sleep deprivation in rats. Neurosci Lett 1997, 235:25-28.
9. D'Almeida V., Lobo L.L., Hipolide D.C., de Oliveira A.C., Nobrega J.N., Tufik S. Sleep deprivation induces brain region-specific decreases in glutathione levels. Neuroreport 1998, 9:2853-2856.
10. Dauvilliers Y. Insomnia in patients with neurodegenerative conditions. Sleep Med 2007, 8(Suppl. 4):S27-34.
11. de Diego-Otero Y., Romero-Zerbo Y., el Bekay R., Decara J., Sanchez L., Rodriguez-de Fonseca F., del Arco-Herrera I. Alpha-tocopherol protects against oxidative stress in the fragile X knockout mouse: an experimental therapeutic approach for the Fmr1 deficiency. Neuropsychopharmacology 2009, 34:1011-1026.
12. De Pasquale R., Beckhauser T.F., Hernandes M.S., Giorgetti Britto L.R. LTP and LTD in the visual cortex require the activation of NOX2. J Neurosci 2014, 34:12778-12787.
13. Di Meco A., Joshi Y.B., Pratico D. Sleep deprivation impairs memory, tau metabolism, and synaptic integrity of a mouse model of Alzheimer's disease with plaques and tangles. Neurobiol Aging 2014, 35:1813-1820.
14. el Bekay R., Romero-Zerbo Y., Decara J., Sanchez-Salido L., Del Arco-Herrera I., Rodriguez-de Fonseca F., de Diego-Otero Y. Enhanced markers of oxidative stress, altered antioxidants and NADPH-oxidase activation in brains from Fragile X mental retardation 1-deficient mice, a pathological model for Fragile X syndrome. Eur J Neurosci 2007, 26:3169-3180.
15. Esposito E., Cuzzocrea S. Antiinflammatory activity of melatonin in central nervous system. Curr Neuropharmacol 2010, 8:228-242.
16. Everson C.A., Laatsch C.D., Hogg N. Antioxidant defense responses to sleep loss and sleep recovery. Am J Physiol Regul Integr Comp Physiol 2005, 288:R374-383.
17. Finkel T. Oxidant signals and oxidative stress. Curr Opin Cell Biol 2003, 15:247-254.
18. Frey D.J., Fleshner M., Wright K.P. The effects of 40hours of total sleep deprivation on inflammatory markers in healthy young adults. Brain Behav Immun 2007, 21:1050-1057.
19. Galano A., Tan D.X., Reiter R.J. On the free radical scavenging activities of melatonin's metabolites, AFMK and AMK. J Pineal Res 2013, 54:245-257.
20. Ghilan M., Hryciw B.N., Brocardo P.S., Bostrom C.A., Gil-Mohapel J., Christie B.R. Enhanced corticosteroid signaling alters synaptic plasticity in the dentate gyrus in mice lacking the fragile X mental retardation protein. Neurobiol Dis 2015, 77:26-34.
21. Goldman S.E., Adkins K.W., Calcutt M.W., Carter M.D., Goodpaster R.L., Wang L., Shi Y., Burgess H.J., Hachey D.L., Malow B.A. Melatonin in children with autism spectrum disorders: endogenous and pharmacokinetic profiles in relation to sleep. J Autism Dev Disord 2014, 44:2525-2535.
22. Gopalakrishnan A., Ji L.L., Cirelli C. Sleep deprivation and cellular responses to oxidative stress. Sleep 2004, 27:27-35.
23. Hamilton A., Esseltine J.L., DeVries R.A., Cregan S.P., Ferguson S.S. Metabotropic glutamate receptor 5 knockout reduces cognitive impairment and pathogenesis in a mouse model of Alzheimer's disease. Mol Brain 2014, 7:40.
24. Havekes R., Vecsey C.G., Abel T. The impact of sleep deprivation on neuronal and glial signaling pathways important for memory and synaptic plasticity. Cell Signal 2012, 24(6):1251-1260.
25. Hitchler M.J., Domann F.E. An epigenetic perspective on the free radical theory of development. Free Radical Biol Med 2007, 43:1023-1036.
26. Irwin M.R., Witarama T., Caudill M., Olmstead R., Breen E.C. Sleep loss activates cellular inflammation and signal transducer and activator of transcription (STAT) family proteins in humans. Brain Behav Immun 2014.
27. Jan J.E., Bax M.C., Owens J.A., Ipsiroglu O.S., Wasdell M.B. Neurophysiology of circadian rhythm sleep disorders of children with neurodevelopmental disabilities. Eur J Paediatr Neurol 2012, 16:403-412.
28. Jan J.E., Reiter R.J., Bax M.C., Ribary U., Freeman R.D., Wasdell M.B. Long-term sleep disturbances in children: a cause of neuronal loss. Eur J Paediatr Neurol 2010, 14(5):380-390.
29. Jenwitheesuk A., Nopparat C., Mukda S., Wongchitrat P., Govitrapong P. Melatonin regulates aging and neurodegeneration through energy metabolism, epigenetics, autophagy and circadian rhythm pathways. Int J Mol Sci 2014, 15:16848-16884.
30. Jeon S.J., Seo J.E., Yang S.I., Choi J.W., Wells D., Shin C.Y., Ko K.H. Cellular stress-induced up-regulation of FMRP promotes cell survival by modulating PI3K-Akt phosphorylation cascades. J Biomed Sci 2011, 18:17.
31. Jeon S.J., Han S.H., Yang S.I., Choi J.W., Kwon K.J., Park S.H., Kim H.Y., Cheong J.H., Ryu J.H., Ko K.H., Wells D.G., Shin C.Y. Positive feedback regulation of Akt-FMRP pathway protects neurons from cell death. J Neurochem 2012, 123:226-238.
32. Kayumov L., Brown G., Jindal R., Buttoo K., Shapiro C.M. A randomized, double-blind, placebo-controlled crossover study of the effect of exogenous melatonin on delayed sleep phase syndrome. Psychosom Med 2001, 63:40-48.
33. Kooy R.F. Of mice and the fragile X syndrome. Trends Genet 2003, 19:148-154.
34. Kumar A., Singh A., Kumar P. Possible involvement of GABAergic mechanism in protective effect of melatonin against sleep deprivation-induced behavior modification and oxidative damage in mice. Indian J Exp Biol 2011, 49:211-218.
35. Kwon K.J., Kim J.N., Kim M.K., Lee J., Ignarro L.J., Kim H.J., Shin C.Y., Han S.H. Melatonin synergistically increases resveratrol-induced heme oxygenase-1 expression through the inhibition of ubiquitin-dependent proteasome pathway: a possible role in neuroprotection. J Pineal Res 2011, 50:110-123.
36. Mauriz J.L., Collado P.S., Veneroso C., Reiter R.J., Gonzalez-Gallego J. A review of the molecular aspects of melatonin's anti-inflammatory actions: recent insights and new perspectives. J Pineal Res 2013, 54:1-14.
37. McCurry S.M., Reynolds C.F., Ancoli-Israel S., Teri L., Vitiello M.V. Treatment of sleep disturbance in Alzheimer's disease. Sleep Med Rev 2000, 4:603-628.
38. Metodiewa D., Koska C. Reactive oxygen species and reactive nitrogen species: relevance to cyto(neuro)toxic events and neurologic disorders. An overview. Neurotox Res 2000, 1:197-233.
39. Mor M., Rivara S., Pala D., Bedini A., Spadoni G., Tarzia G. Recent advances in the development of melatonin MT(1) and MT(2) receptor agonists. Expert Opin Ther Pat 2010, 20:1059-1077.
40. Musiek E.S., Xiong D.D., Holtzman D.M. Sleep, circadian rhythms, and the pathogenesis of Alzheimer disease. Exp Mol Med 2015, 13(47):e148.
41. Naguib M., Gottumukkala V., Goldstein P.A. Melatonin and anesthesia: a clinical perspective. J Pineal Res 2007, 42:12-21.
42. Padmashri R., Reiner B.C., Suresh A., Spartz E., Dunaevsky A. Altered structural and functional synaptic plasticity with motor skill learning in a mouse model of fragile X syndrome. J Neurosci 2013, 33(50):19715-19723.
43. Pagan C., Delorme R., Callebert J., Goubran-Botros H., Amsellem F., Drouot X., Boudebesse C., Le Dudal K., Ngo-Nguyen N., Laouamri H., Gillberg C., Leboyer M., Bourgeron T., Launay J.M. The serotonin-N-acetylserotonin-melatonin pathway as a biomarker for autism spectrum disorders. Transl Psychiatry 2014, 4:e479.
44. Pandi-Perumal S.R., BaHammam A.S., Brown G.M., Spence D.W., Bharti V.K., Kaur C., Hardeland R., Cardinali D.P. Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes. Neurotox Res 2013, 23:267-300.
45. Perluigi M., Di Domenico F., Butterfield D.A. mTOR signaling in aging and neurodegeneration: at the crossroad between metabolism dysfunction and impairment of autophagy. Neurobiol Dis 2015.
46. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008, 22:659-661.
47. Reiter R.J., Tan D.X. Role of CSF in the transport of melatonin. J Pineal Res 2002, 33:61.
48. Reiter R.J., Tan D.X., Fuentes-Broto L. Melatonin: a multitasking molecule. Prog Brain Res 2010, 181:127-151.
49. Reiter R.J., Tan D.X., Kim S.J., Cruz M.H. Delivery of pineal melatonin to the brain and SCN: role of canaliculi, cerebrospinal fluid, tanycytes and Virchow-Robin perivascular spaces. Brain Struct Funct 2014, 219:1873-1887.
50. Renoux A.J., Carducci N.M., Ahmady A.A., Todd P.K. Fragile X mental retardation protein expression in Alzheimer's disease. Front Genet 2014, 5:360.
51. Romero-Zerbo Y., Decara J., el Bekay R., Sanchez-Salido L., Del Arco-Herrera I., de Fonseca F.R., de Diego-Otero Y. Protective effects of melatonin against oxidative stress in Fmr1 knockout mice: a therapeutic research model for the fragile X syndrome. J Pineal Res 2009, 46:224-234.
52. Rosales-Corral S.A., Acuna-Castroviejo D., Coto-Montes A., Boga J.A., Manchester L.C., Fuentes-Broto L., Korkmaz A., Ma S., Tan D.X., Reiter R.J. Alzheimer's disease: pathological mechanisms and the beneficial role of melatonin. J Pineal Res 2012, 52:167-202.
53. Rudnitskaya E.A., Maksimova K.Y., Muraleva N.A., Logvinov S.V., Yanshole L.V., Kolosova N.G., Stefanova N.A. Beneficial effects of melatonin in a rat model of sporadic Alzheimer's disease. Biogerontology 2014.
54. Scullin M.K., Bliwise D.L. Sleep, cognition, and normal aging: integrating a half century of multidisciplinary research. Perspect Psychol Sci 2015, 10(1):97-137.
55. Shen Y.X., Xu S.Y., Wei W., Sun X.X., Yang J., Liu L.H., Dong C. Melatonin reduces memory changes and neural oxidative damage in mice treated with d-galactose. J Pineal Res 2002, 32:173-178.
56. Skene D.J., Swaab D.F. Melatonin rhythmicity: effect of age and Alzheimer's disease. Exp Gerontol 2003, 38:199-206.
57. Sokol D.K., Maloney B., Long J.M., Ray B., Lahiri D.K. Autism, Alzheimer disease, and fragile X: APP, FMRP, and mGluR5 are molecular links. Neurology 2011, 76:1344-1352.
58. Srinivasan V., Kaur C., Pandi-Perumal S., Brown G.M., Cardinali D.P. Melatonin and its agonist ramelteon in Alzheimer's disease: possible therapeutic value. Int J Alzheimers Dis 2010, 2011:741974.
59. Takeda S., Sato N., Morishita R. Systemic inflammation, blood-brain barrier vulnerability and cognitive/non-cognitive symptoms in Alzheimer disease: relevance to pathogenesis and therapy. Front Aging Neurosci 2014, 29(6):171.
60. Tamanini F., Meijer N., Verheij C., Willems P.J., Galjaard H., Oostra B.A., Hoogeveen A.T. FMRP is associated to the ribosomes via RNA. Hum Mol Genet 1996, 5:809-813.
61. Udagawa T., Farny N.G., Jakovcevski M., Kaphzan H., Alarcon J.M., Anilkumar S., Ivshina M., Hurt J.A., Nagaoka K., Nalavadi V.C., Lorenz L.J., Bassell G.J., Akbarian S., Chattarji S., Klann E., Richter J.D. Genetic and acute CPEB1 depletion ameliorate fragile X pathophysiology. Nat Med 2013.
62. Villa C., Ferini-Strambi L., Combi R. The synergistic relationship between Alzheimer's disease and sleep disorders: an update. J Alzheimers Dis 2015.
63. Westmark C.J., Westmark P.R., O'Riordan K.J., Ray B.C., Hervey C.M., Salamat M.S., Abozeid S.H., Stein K.M., Stodola L.A., Tranfaglia M., Burger C., Berry-Kravis E.M., Malter J.S. Reversal of fragile X phenotypes by manipulation of AbetaPP/Abeta levels in Fmr1KO mice. PLoS One 2011, 6:e26549.
64. Wilhelmsen M., Amirian I., Reiter R.J., Rosenberg J., Gogenur I. Analgesic effects of melatonin: a review of current evidence from experimental and clinical studies. J Pineal Res 2011, 51:270-277.
65. Zhang H.M., Zhang Y. Melatonin: a well-documented antioxidant with conditional pro-oxidant actions. J Pineal Res 2014, 57:131-146.
66. Zhang L., Zhang H.Q., Liang X.Y., Zhang H.F., Zhang T., Liu F.E. Melatonin ameliorates cognitive impairment induced by sleep deprivation in rats: role of oxidative stress, BDNF and CaMKII. Behav Brain Res 2013, 256:72-81.
67. Zhou J.N., Liu R.Y., Kamphorst W., Hofman M.A., Swaab D.F. Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res 2003, 35:125-130.